

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **JACOBIO PHARMACEUTICALS GROUP CO., LTD.**

**加科思藥業集團有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1167)**

### **CHANGE OF JOINT COMPANY SECRETARY, AUTHORISED REPRESENTATIVE AND PROCESS AGENT AND WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES**

#### **CHANGE OF JOINT COMPANY SECRETARY, AUTHORIZED REPRESENTATIVE AND PROCESS AGENT**

The Board of Directors (the “**Board**”) of Jacobio Pharmaceuticals Group Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) has been informed that Mr. Yim Lok Kwan (嚴洛鈞) (“**Mr. Yim**”) has tendered his resignation as (i) the joint company secretary of the Company (the “**Joint Company Secretary(ies)**”); (ii) an authorised representative of the Company (the “**Authorised Representative**”) under Rule 3.05 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”); and (iii) an authorised representative of the Company under Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) for the acceptance of service of process and notices on behalf of the Company in Hong Kong (the “**Process Agent**”) with effect from August 24, 2022.

Mr. Yim has confirmed that he has no disagreement with the Board and that there are no circumstances relating to his resignation which needs to be brought to the attention of the Stock Exchange and the shareholders of the Company.

The Board further announces that Mr. Chung Ming Fai (鍾明輝) (“**Mr. Chung**”) has been appointed as a Joint Company Secretary, the Authorised Representative and the Process Agent with effect from August 24, 2022.

The biographical details of Mr. Chung and the other Joint Company Secretary, Ms. Qing Xue (薛青) (“**Ms. Xue**”), are set out as follows:

Mr. Chung is a vice president of SWCS Corporate Services Group (Hong Kong) Limited and has over 17 years of experience in corporate secretary, mergers and acquisitions, financial reporting and auditing. Mr. Chung is currently a fellow of the Hong Kong Institute of Certified Public Accountants and a member of CPA Australia. He obtained his bachelor’s degree in commerce from the Australian National University.

Ms. Xue was appointed as our joint company secretary on August 20, 2020. Ms. Xue joined Beijing Jacobio in August 2019 and is currently serving as the senior finance director, where she is responsible for the day-to-day financial management. Prior to joining our Group, from January 2010 to July 2019, Ms. Xue worked at an international accounting firm where she served as a senior audit manager prior to her resignation. Ms. Xue obtained her bachelor's degree in international accounting in July 2010 from Capital University of Economics and Business (首都經濟貿易大學) in China. Ms. Xue is currently a member of the American Institute of Certified Public Accountants, a certified public accountant of the State Board of Accountancy of the Commonwealth of Virginia, a member and a fellow of the Association of Chartered Certified Accountants, a member of the Chartered Professional Accountants of British Columbia and a non-practising member of The Chinese Institute of Certified Public Accountants.

The Board is of the view that, having regard to Mr. Chung's relevant experience, Mr. Chung will be able to advise both Ms. Xue and the Company on the relevant requirements of the Listing Rules as well as other applicable laws and regulations. Mr. Chung will assist Ms. Xue to enable her to discharge her duties and responsibilities as a joint company secretary of the Company. Mr. Chung is considered a suitable candidate to act as the Joint Company Secretary.

## **WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES**

Reference is made to the waiver (the "**Waiver**") granted to the Company by the Stock Exchange from strict compliance with the requirements of Rules 3.28 and 8.17 of the Listing Rules in respect of the eligibility of Ms. Xue to act as a Joint Company Secretary for a three-year period from the date of the Company's listing (i.e. December 21, 2020) (the "**Waiver Period**"), on the condition that Ms. Xue would be assisted by Mr. Yim, who possesses the qualifications required under Rule 3.28 of the Listing Rules, during the Waiver Period. Relevant details of the Waiver were disclosed in the section headed "Waivers from Strict Compliance with the Listing Rules and Exemption from Compliance with the Companies (Winding Up and Miscellaneous Provisions) Ordinance" of the prospectus of the Company dated December 9, 2020 and the announcement of the Company dated March 26, 2021.

Given the condition of the Waiver could no longer be fulfilled following the resignation of Mr. Yim, the Company has applied to the Stock Exchange and has been granted with a new waiver (the "**New Waiver**") by the Stock Exchange from strict compliance with the requirements under Rules 3.28 and 8.17 of the Listing Rules for the remaining period of the Waiver Period (the "**Remaining Waiver Period**") in relation to the eligibility of Ms. Xue to act as a Joint Company Secretary, on the conditions that:

- (i) Ms. Xue must be assisted by Mr. Chung during the Remaining Waiver Period; and
- (ii) the New Waiver can be revoked if there are material breaches of the Listing Rules by the Company.

Before the end of the Remaining Waiver Period, the Company must demonstrate and seek the Stock Exchange's confirmation that Ms. Xue, having had the benefit of Mr. Chung's assistance during the Remaining Waiver Period, has attained the relevant experience and is capable of discharging the functions of company secretary under Rule 3.28 of the Listing Rules such that a further waiver will not be necessary.

The Board would like to take this opportunity to express its gratitude to Mr. Yim for his contribution to the Company during his tenure of service and welcome Mr. Chung on his new appointment.

On behalf of the Board  
**JACOBIO PHARMACEUTICALS GROUP CO., LTD.**  
**Yinxiang WANG**  
*Chairman*

Hong Kong, August 24, 2022

*As at the date of this announcement, the Board of the Company comprises Dr. Yinxiang WANG as Chairman and executive Director, Ms. Xiaojie WANG and Ms. Yunyan HU as executive Directors, Ms. Yanmin TANG, Dr. Dong LYU and Dr. Te-li CHEN as non-executive Directors, and Dr. Ruilin SONG, Dr. Ge WU and Dr. Daqing CAI as independent non-executive Directors.*